According to diplomatic sources, Cabrisas, who is also Minister of Foreign Trade and Foreign Investment, toured the place and learnt details about the investigations being carried out there.
According to a publication on social networks by the Cuban ambassador to China, Alberto Blanco, Cabrisas also explained that BPL is a symbol of economic, commercial, and financial relations.
The chairman of BPL, Bai Xianhong, recently praised the biotechnological cooperation between China and Cuba and its positive impact on China.
The chairman thanked the Cuban experts for their contributions in the approval process of the humanized monoclonal antibody Nimotuzumab for the treatment of pancreatic cancer, which was the first product marketed by BPL and the first humanized monoclonal antibody in China since 2008, which obtained very positive results in the fight against nasopharyngeal cancer.
Yanet Borrego, deputy general director and representative of the Cuban vice presidency of BPL, recently told Prensa Latina that the decision of the Chinese Medicines Administration supports the results of years of work.
The Drug Administration referred to the good results of the antibody in clinical studies, its effectiveness in inhibiting the growth of malignant cells and its widespread use in Cuba and other nations of the world since 1998. It also noted that this helps consolidate the presence of Cuban biotechnology products in China, hoping to reach other places where there are also access opportunities.